Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 10/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.36 |
| ▸ | MAOA | P21397 | 3/20 | 0.35 |
| ▸ | MAOB | P27338 | 3/20 | 0.35 |
| ▸ | NISCH | Q9Y2I1 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3775342 | 1.00 | SIGMAR1 (0.40) | SIGMAR1LRRK2MAPK8MAPK1MAOA | |
| SCHEMBL3764048 | 0.84 | LRRK2 (0.53) | LRRK2 | |
| SCHEMBL382684 | 0.84 | LRRK2 (0.53) | LRRK2 | |
| SCHEMBL19566976 | 0.83 | LRRK2 (0.43) | LRRK2 | |
| SCHEMBL3774953 | 0.82 | LRRK2 (0.43) | LRRK2 | |
| SCHEMBL19564540 | 0.82 | LRRK2 (0.43) | LRRK2 | |
| SCHEMBL3778607 | 0.81 | L3MBTL1 (0.47) | LRRK2MAPK8MAPK1MAOA | |
| SCHEMBL3771912 | 0.78 | LRRK2 (0.46) | LRRK2 | |
| SCHEMBL3775321 | 0.78 | LRRK2 (0.46) | LRRK2 | |
| SCHEMBL16857691 | 0.78 | LRRK2 (0.46) | LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170320870-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2017-11-09 | — | — | US | disclosed |
| US-20170320870-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2017-11-09 | — | — | US | disclosed |
| US-20170320870-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2017-11-09 | — | — | US | disclosed |
| EP-2408772-B1 | COMPOUNDS | MEDICAL RES COUNCIL TECHNOLOGY (GB) | 2015-07-01 | — | — | EP | disclosed |
| US-20100317646-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-12-16 | — | — | US | disclosed |
| US-20100317646-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-12-16 | — | — | US | disclosed |
| US-20100317646-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170320870-A1 | COMPOUNDS | CBR3, CNR1, HCAR3 | SIGMAR1 124/4885LRRK2 2309/4885MAPK8 1739/4885 |
| US-20100317646-A1 | COMPOUNDS | CBR3, CNR1, HCAR3 | SIGMAR1 116/4885LRRK2 2208/4885MAPK8 1759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.